HOME >> BIOLOGY >> NEWS
Does evolution select for faster evolvers?

HOUSTON, Jan. 29, 2007 -- It's a mystery why the speed and complexity of evolution appear to increase with time. For example, the fossil record indicates that single-celled life first appeared about 3.5 billion years ago, and it then took about 2.5 billion more years for multi-cellular life to evolve. That leaves just a billion years or so for the evolution of the diverse menagerie of plants, mammals, insects, birds and other species that populate the earth.

New studies by Rice University scientists suggest a possible answer; the speed of evolution has increased over time because bacteria and viruses constantly exchange transposable chunks of DNA between species, thus making it possible for life forms to evolve faster than they would if they relied only on sexual selection or random genetic mutations.

"We have developed the first exact solution of a mathematical model of evolution that accounts for this cross-species genetic exchange," said Michael Deem, the John W. Cox Professor in Biochemical and Genetic Engineering and professor of physics and astronomy.

The research appears in the Jan. 29 issue of Physical Review Letters.

Past mathematical models of evolution have focused largely on how populations respond to point mutations random changes in single nucleotides on the DNA chain, or genome. A few theories have focused on recombination the process that occurs in sexual selection when the genetic sequences of parents are recombined.

Horizontal gene transfer (HGT) is a cross-species form of genetic transfer. It occurs when the DNA from one species is introduced into another. The idea was ridiculed when first proposed more than 50 years ago, but the advent of drug-resistant bacteria and subsequent discoveries, including the identification of a specialized protein that bacteria use to swap genes, has led to wide acceptance in recent years.

"We know that the majority of the DNA in the genomes of some anim
'"/>

Contact: Jade Boyd
jadeboyd@rice.edu
713-348-6778
Rice University
29-Jan-2007


Page: 1 2

Related biology news :

1. Clones on task serve greater good, evolutionary study shows
2. New textbook illuminates the close links between evolutionary and molecular biology
3. Coelacanth fossil sheds light on fin-to-limb evolution
4. Genomics study provides insight into the evolution of unique human traits
5. New proteomics research promises to revolutionize biomedical discovery
6. Species detectives track unseen evolution
7. Study identifies energy efficiency as reason for evolution of upright walking
8. Clues to future evolution of HIV come from African green monkeys
9. Tumor painting revolutionizes fight against cancer
10. Revolutionary global environment fund announces $50M expansion
11. A first-principles model of early evolution

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Does evolution select for faster evolvers

(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... at Charlotte (UNC Charlotte) spin-out company, announced today ... Cooper, Ph.D., M.D., as Chief Operating Officer (COO). ... of experience in developing clinical diagnostic and biotechnology ... infectious disease. , Cooper’s extensive career transcends the ...
(Date:4/16/2015)... 16, 2015  In recognition of World Hemophilia Day, ... groups to illuminate more than 15 prominent landmarks red throughout ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... of April 17, and coincide with hemophilia community events in ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: